var data={"title":"Pharmacology of echinocandins","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pharmacology of echinocandins</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/contributors\" class=\"contributor contributor_credentials\">Russell E Lewis, PharmD, FCCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 29, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1239292403\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The development of echinocandins, the first class of antifungals to target the fungal cell wall, was a milestone achievement in antifungal chemotherapy. Echinocandins were discovered as fermentation metabolites with antifungal activity during screening programs for new antibiotics [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/1\" class=\"abstract_t\">1</a>]. The candidate molecules were subsequently modified to improve solubility, antifungal spectrum of activity, and pharmacokinetic characteristics [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/2\" class=\"abstract_t\">2</a>]. Three semi-synthetic echinocandin derivatives have been developed for clinical use: <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, and <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>.</p><p>All three echinocandins are structurally similar cyclic hexapeptide antibiotics with modified N-linked acyl lipid side chains (<a href=\"image.htm?imageKey=ID%2F70049\" class=\"graphic graphic_figure graphicRef70049 \">figure 1</a>), which play a role in anchoring the hexapeptide nucleus to the fungal cell membrane where the drug interacts with the target enzyme complex involved in cell wall synthesis [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3\" class=\"abstract_t\">3</a>]. Like other large lipopeptide antibiotics, these drugs have limited oral bioavailability and must be administered by intravenous infusion. Experience with this antifungal class suggests that it is among the best tolerated and safest class of antifungals available.</p><p>The pharmacology of echinocandin antifungals will be reviewed here. Indications for the clinical use of echinocandins, antifungal susceptibility testing, and the pharmacology of other systemic antifungal agents, such as amphotericin B, the azoles, and <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, are discussed separately. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;</a> and <a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">&quot;Antifungal susceptibility testing&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-flucytosine-5-fc\" class=\"medical medical_review\">&quot;Pharmacology of flucytosine (5-FC)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1239292410\"><span class=\"h1\">OVERVIEW OF CLINICAL USES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically ill and neutropenic patients [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/4\" class=\"abstract_t\">4</a>]. They are also used for empiric antifungal therapy in patients with neutropenic fever. They are sometimes used in combination with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> for the initial treatment of invasive aspergillosis or as part of a combination antifungal regimen with voriconazole or a lipid formulation of amphotericin B for salvage therapy of invasive aspergillosis. (See <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;</a>.)</p><p>The major advantages of echinocandins relative to other antifungal agents are their fungicidal activity against <em>Candida</em> spp, including fluconazole-resistant <em>C. glabrata</em> and <em>C. krusei</em>, combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions. Specific recommendations regarding the use of these agents are presented separately. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients#H154974350\" class=\"medical medical_review\">&quot;Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)&quot;, section on 'Addition of an antifungal agent'</a>.)</p><p>All three echinocandins have been approved by the US Food and Drug Administration (FDA) for the treatment of esophageal candidiasis and invasive candidiasis in adults, and <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> has been approved for these indications in children over three months of age. Caspofungin has also been FDA approved as an empiric antifungal agent for febrile neutropenia and for salvage therapy of invasive aspergillosis in patients who have failed or are intolerant of other antifungal agents in adults and children over three months of age. <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> has also been FDA approved as a prophylactic agent for the prevention of <em>Candida </em>infections in adults undergoing hematopoietic cell transplantation.</p><p>Because all three echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a>.)</p><p>However, the three echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, these unique characteristics should be considered when selecting an echinocandin.</p><p class=\"headingAnchor\" id=\"H1239299741\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanism of action of the echinocandins exploits a biochemical pathway unique to fungi, which is different from the mechanisms of other antifungal drugs. Echinocandins are believed to elicit their antifungal activity by binding to the Fks p subunit of the enzyme, thereby blocking the b-(1,3)-D-glucan synthesis (<a href=\"image.htm?imageKey=ID%2F67408\" class=\"graphic graphic_figure graphicRef67408 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/5\" class=\"abstract_t\">5</a>]. This enzyme complex is composed of at least two components: catalytic subunits called Fks1p and Fks2p, and a GTP-binding protein, Rho1, which regulate the activity of glucan synthesis. Beta-glucans, when cross-linked to chitin and mannoproteins, provide structural integrity to cell walls of various pathogenic fungi and molds including <em>Candida</em> spp, <em>Aspergillus</em> spp, and <em>Pneumocystis jirovecii</em>.</p><p>Beta-glucans account for approximately 30 to 60 percent of the cell wall mass in yeasts such as <em>Candida</em> species [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Beta-glucan depletion causes loss of resistance to osmotic forces and cell lysis among <em>Candida</em> spp, thereby having a fungicidal effect. In filamentous fungi, such as <em>Aspergillus fumigatus</em>, the bulk of beta-glucan synthesis is concentrated at the apical tips and branching points of hyphae [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/8-10\" class=\"abstract_t\">8-10</a>]. Among filamentous fungi, echinocandin-induced beta-glucan depletion causes impeded growth at the tips and branching points of hyphae, resulting in dysmorphic hyphae; this growth inhibition has a fungistatic effect [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Beta-glucans and the intracellular beta-glucan synthase complex blocked by echinocandins are not present in human cells. For this reason, the echinocandins cause less toxicity than amphotericin B formulations or the triazoles and are implicated in fewer drug-drug interactions. In addition, the mechanism of action of the echinocandins appears to complement the antifungal effects of the other antifungal drug classes, offering the potential for combination therapy. (See <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis#H19\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;, section on 'Combination therapy'</a>.)</p><p>Echinocandins<strong> </strong>may also amplify host immune responses by unmasking beta-glucan epitopes, which are highly antigenic, thereby accelerating host cellular recognition and inflammatory responses [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/12-16\" class=\"abstract_t\">12-16</a>]. However, the evidence supporting such immunomodulatory effects is limited to in vitro studies and murine models.</p><p class=\"headingAnchor\" id=\"H1239292431\"><span class=\"h1\">MICROBIOLOGIC ACTIVITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Given the widespread distribution of beta-glucans in the fungal cell wall and the high degree of homology of <em>FKS</em> genes among diverse fungal genera, echinocandins would be predicted to exhibit activity against a wide spectrum of fungal pathogens. However, the echinocandins are primarily effective against <em>Candida </em>and <em>Aspergillus</em> species, with relatively weak activity against other molds and yeasts, including <em>Cryptococcus neoformans</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3\" class=\"abstract_t\">3</a>]. Differences in fungal cell wall construction may influence echinocandin penetration or render some fungal species less susceptible to the effects of beta-glucan synthesis inhibition [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H1239292438\"><span class=\"h2\">Candida species</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All three of the echinocandins exhibit excellent potency against <em>Candida</em> spp [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/17\" class=\"abstract_t\">17</a>]. <em>C. albicans</em>, <em>C. glabrata</em>, and <em>C. tropicalis</em> are highly susceptible to all three agents, whereas elevated minimum inhibitory concentrations (MICs) have been seen for <em>C. parapsilosis</em> and <em>C. guilliermondii</em> (<a href=\"image.htm?imageKey=ID%2F107624\" class=\"graphic graphic_table graphicRef107624 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Acquired resistance to the echinocandins remains sporadic [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/19,20\" class=\"abstract_t\">19,20</a>] but has been documented for individual cases of infection with <em>C. albicans</em>, <em>C. glabrata</em>, <em>C. lusitaniae</em>, <em>C. tropicalis</em>, and <em>C. parapsilosis</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/20-26\" class=\"abstract_t\">20-26</a>].<br/><br/>Of note, there is increasing concern that some <em>C. glabrata</em> bloodstream isolates with resistance to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> are also resistant to the echinocandins. In a surveillance study of the in vitro susceptibility of 1669 <em>C. glabrata</em> bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to fluconazole, of which 98.8 percent were also not susceptible to voriconazole (MIC &gt;0.5 <span class=\"nowrap\">mcg/mL),</span> and 9.3, 9.3, and 8.0 percent were resistant to <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>, <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, and <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, respectively [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/18\" class=\"abstract_t\">18</a>]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an <em>FKS1</em> or <em>FKS2</em> mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant <em>C. glabrata</em> isolates tested between 2001 and 2004, years in which only one echinocandin, caspofungin, was available, and echinocandins were used sparingly. In a population-based analysis of echinocandin resistance in 1380 bloodstream isolates of <em>C. glabrata</em> from four United States cities collected between 2008 and 2013, 3 to 4 percent of strains were resistant to all three echinocandins, and approximately one-third of echinocandin-resistant strains were cross-resistant to fluconazole [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/27\" class=\"abstract_t\">27</a>]. Nearly all of the isolates with an <em>FKS1</em> or <em>FKS2</em> mutation were resistant to at least one echinocandin.<br/><br/>A 10-year study of <em>C. glabrata</em> bloodstream infections at a single medical center in the United States showed an increase in echinocandin resistance from 4.9 percent in 2001 to 12.3 percent in 2010 [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/28\" class=\"abstract_t\">28</a>]. This resistance was confirmed by the presence of <em>FKS</em> mutations; strains categorized as susceptible did not possess acquired mutations. On multivariate analysis, echinocandin resistance was associated with prior exposure to an echinocandin. Among 118 episodes of <em>C. glabrata</em> infection in which the infecting strain was categorized as susceptible using the clinical breakpoints, 109 (92.4 percent) had successful outcomes at day 10 of treatment with micafungin. Conversely, among 13 episodes of <em>C. glabrata</em> infection in which the strain was categorized as resistant using the clinical breakpoints and treated with micafungin monotherapy, 5 (38.5 percent) did not respond or responded initially but relapsed or recurred. Among 78 fluconazole-resistant isolates, 11 (14.1 percent) were resistant to one or more echinocandins and 8 (10.3 percent) were resistant to all echinocandins. Another retrospective single-center study reported that <em>FKS</em> mutations were identified in 18 percent of 72 patients with <em>C. glabrata</em> candidemia and were associated with an eightfold risk of treatment failure [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/29\" class=\"abstract_t\">29</a>].<br/><br/>Among patients with underlying hematologic disease, infection with an echinocandin-resistant strain of <em>C. glabrata, C. parapsilosis, or C. tropicalis</em> was associated with threefold higher rates of 14- and 30-day mortality [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/30\" class=\"abstract_t\">30</a>].<br/><br/>These findings argue for continued surveillance for resistance using standardized antifungal susceptibility testing. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1690258277\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'Susceptibility patterns'</a> and <a href=\"topic.htm?path=antifungal-susceptibility-testing#H28\" class=\"medical medical_review\">&quot;Antifungal susceptibility testing&quot;, section on 'Echinocandins'</a>.)</p><p class=\"headingAnchor\" id=\"H1239292445\"><span class=\"h3\">Candida biofilms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins are unique among the systemic antifungal agents in their activity against biofilm-embedded <em>Candida</em> species. Under sessile biofilm-like conditions, the MICs for amphotericin B and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> may increase by 10- to 1000-fold [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/31,32\" class=\"abstract_t\">31,32</a>]. Biofilm growth in <em>C. albicans</em> is associated with increased secretion of carbohydrates, including beta-1,3-D-glucan [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/33\" class=\"abstract_t\">33</a>], which has been shown to directly inhibit the activity of both fluconazole and amphotericin B [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/34-36\" class=\"abstract_t\">34-36</a>]. In contrast, echinocandin MICs are minimally affected when tested in biofilm versus non-biofilm conditions, and a biofilm-embedded inoculum of <em>C. albicans</em> can be reduced by &gt;99 percent at the echinocandin concentrations achieved in vivo [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/31,32\" class=\"abstract_t\">31,32</a>]. These in vitro data suggest that echinocandins may be particularly useful antifungal agents for prosthetic device or catheter-associated infections in which biofilm-embedded organisms can be associated with recurrent candidemia.</p><p class=\"headingAnchor\" id=\"H1239292452\"><span class=\"h2\">Other yeasts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins lack clinically useful activity against <em>Trichosporon</em> spp, <em>Cryptococcus neoformans</em>, and <em>Cryptococcus gattii</em>, even though beta-1,3-D-glucan synthase from <em>Cryptococcus</em> spp is exquisitely sensitive to inhibition by <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, and beta-1,3-D-glucan is present in the fungal cell wall [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3\" class=\"abstract_t\">3</a>]. Compensatory cell wall mechanisms, melanin, and drug degradation pathways may contribute to the inherent resistance of this species to echinocandins.</p><p class=\"headingAnchor\" id=\"H1239292466\"><span class=\"h2\">Dimorphic fungi</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins have only modest activity against the mycelial phase of the dimorphic fungi, <em>Blastomyces dermatitidis</em>, <em>Histoplasma capsulatum</em>, and <em>Coccidioides</em> spp. Echinocandins are not considered to be effective agents for therapy of dimorphic fungal infections.</p><p class=\"headingAnchor\" id=\"H1239292473\"><span class=\"h2\">Aspergillus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Growth of <em>Aspergillus</em> species is inhibited at very low echinocandin concentrations in vitro, with the effects predominantly observed at apical and sub-apical branching points where cell wall remodeling and beta-glucan synthase are most active [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/9,37\" class=\"abstract_t\">9,37</a>]. As such, MIC endpoints for <em>Aspergillus </em>are determined differently for echinocandins than for other antifungals. The lowest echinocandin concentration resulting in grossly abnormal hyphal forms (small, compact, highly branched hyphae as compared with the normally elongated hyphal forms) are defined at the minimum effective concentration (MEC) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/11\" class=\"abstract_t\">11</a>]. MEC ranges for most <em>Aspergillus</em> species fall into what would be considered the susceptible range (<a href=\"image.htm?imageKey=ID%2F107624\" class=\"graphic graphic_table graphicRef107624 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H1239292480\"><span class=\"h2\">Other molds</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins have only modest or weak activity against non-<em>Aspergillus</em> molds that is sometimes more apparent in vivo than in vitro, suggesting that their effects are partially mediated through unmasking of immunogenic epitopes on the fungal cell wall [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/38\" class=\"abstract_t\">38</a>]. Modest echinocandin activity has been reported in vitro for some phaeohyphomycetes, including <em>Alternaria</em> spp, <em>Bipolaris</em> spp, <em>Cladophialophora bantiana</em>, <em>Phialophora</em> spp, <em>Exophiala</em> spp, <em>Fonsecaea pedrosi</em>, <em>Paecilomyces variotti</em>, <em>Acremonium strictum</em>, and <em>Scedosporium apiospermum</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/39-42\" class=\"abstract_t\">39-42</a>], but echinocandins are <strong>not</strong> used to treat infections due to these organisms.</p><p class=\"headingAnchor\" id=\"H12264177\"><span class=\"h2\">Pneumocystis jirovecii</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In experimental models of <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>) pneumonia (PCP), the echinocandins are effective agents for prophylaxis but are less effective for established pneumonia [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/43,44\" class=\"abstract_t\">43,44</a>]. The limited treatment efficacy of echinocandins can be explained by the fact that the glucan synthase target for echinocandin activity is expressed only during the cystic but not the trophic life cycle of <em>P. jirovecii</em> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/44,45\" class=\"abstract_t\">44,45</a>]. Therefore, fungal clearance of established infection is relatively weak with echinocandins compared with established therapies such as <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/39,46\" class=\"abstract_t\">39,46</a>]. The echinocandins have no role for the treatment or prevention of PCP. (See <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1239292487\"><span class=\"h1\">RESISTANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although echinocandins are used extensively as a first-line treatment for invasive candidiasis and less commonly as part of salvage regimens for invasive aspergillosis, acquired echinocandin resistance has been relatively rare to date but is possibly increasing, especially among <em>C. glabrata</em>. (See <a href=\"#H1239292438\" class=\"local\">'Candida species'</a> above.)</p><p>Echinocandin resistance is discussed in detail separately. (See <a href=\"topic.htm?path=antifungal-susceptibility-testing#H28\" class=\"medical medical_review\">&quot;Antifungal susceptibility testing&quot;, section on 'Echinocandins'</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis#H19\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;, section on 'Combination therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H1239292494\"><span class=\"h1\">PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the echinocandins share similar spectra of activity, each agent differs in its pathway of metabolism, resulting in distinguishable half-lives, drug interaction profiles, and dosing strategies (<a href=\"image.htm?imageKey=ID%2F56212\" class=\"graphic graphic_table graphicRef56212 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3,47\" class=\"abstract_t\">3,47</a>]. Due to their large molecular weights, echinocandins are minimally absorbed after oral administration and are available only in intravenous formulations. All three echinocandins exhibit a high degree of binding to plasma proteins and distribute minimally to cerebrospinal fluid, urine, and the eye. Echinocandins are not primarily metabolized by cytochrome P450 nor are they substrates or inhibitors of P-glycoprotein pumps, making them less likely targets of drug-drug interactions compared with other systemic antifungals. (See <a href=\"#H1239298150\" class=\"local\">'Dosing'</a> below and <a href=\"#H1239298206\" class=\"local\">'Renal insufficiency'</a> below and <a href=\"#H1239299710\" class=\"local\">'Hepatic insufficiency'</a> below and <a href=\"#H1239300816\" class=\"local\">'Drug interactions'</a> below.)</p><p class=\"headingAnchor\" id=\"H22267050\"><span class=\"h2\">Caspofungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> exhibits triphasic nonlinear pharmacokinetics [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. Following an initial intravenous infusion, tissue distribution accounts for an initial rapid fall in plasma levels, followed by gradual re-release of drug from extravascular tissues coupled with slow hepatic metabolism, yielding a net terminal half-life of 27 to 50 hours [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/47,49-51\" class=\"abstract_t\">47,49-51</a>]. A loading dose followed by a lower once-daily dose is therefore required to attain an initial therapeutic plasma level and avoid drug accumulation. Caspofungin degrades spontaneously and is also metabolized via hydrolysis and N-acetylation to two inactive metabolites<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,50\" class=\"abstract_t\">48,50</a>]. It is non-dialyzable, and less than 2 percent of active drug is excreted via the urinary tract.</p><p>Dose adjustment is unnecessary for patients with renal insufficiency. However, dose reduction for severe hepatic insufficiency is recommended. (See <a href=\"#H1239298150\" class=\"local\">'Dosing'</a> below and <a href=\"#H1239301213\" class=\"local\">'Caspofungin'</a> below.)</p><p>Several drugs have been shown to induce the metabolism of <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>: <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a>, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, and <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>. An increased maintenance dose of caspofungin is therefore recommended when any of these agents are given concurrently with caspofungin.</p><p class=\"headingAnchor\" id=\"H22267058\"><span class=\"h2\">Micafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> demonstrates linear elimination pharmacokinetics, producing a terminal half-life of approximately 15 hours in adults [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/47,52\" class=\"abstract_t\">47,52</a>]. It is metabolized hepatically by arylsulfatase, catechol O-methyltransferase, and hydroxylation. Less than 1 percent of unchanged drug is excreted in the urine. Like <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, it is non-dialyzable, and dose adjustment for renal insufficiency is unnecessary. Elimination pharmacokinetics in advanced hepatic insufficiency are not well defined. Micafungin is subject to relatively few drug-drug interactions.</p><p>Modest increases in exposure to <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, and <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">nifedipine</a> have been described in patients receiving <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"#H1239298150\" class=\"local\">'Dosing'</a> below and <a href=\"#H1239300837\" class=\"local\">'Micafungin'</a> below.)</p><p class=\"headingAnchor\" id=\"H22267066\"><span class=\"h2\">Anidulafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> exhibits linear elimination pharmacokinetics that are predictable and relatively stable across a broad range of patient age, weight, gender, and disease states. Anidulafungin is not metabolized but instead eliminated by slow spontaneous degradation, resulting in a terminal half-life of 40 to 50 hours<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/52\" class=\"abstract_t\">52</a>]. A loading dose is necessary to achieve rapid therapeutic concentrations. Less than one percent of unchanged drug is excreted in the urine. It is non-dialyzable and dose adjustment for renal or hepatic insufficiency is unnecessary. Few drug-drug interactions are expected. (See <a href=\"#H1239298150\" class=\"local\">'Dosing'</a> below and <a href=\"#H1239301205\" class=\"local\">'Anidulafungin'</a> below.)</p><p class=\"headingAnchor\" id=\"H1239298142\"><span class=\"h1\">PHARMACODYNAMICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The plasma drug concentration profile that optimizes the antifungal efficacy of echinocandins has been only partly elucidated [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/54\" class=\"abstract_t\">54</a>]. Echinocandins appear to exhibit concentration-dependent killing against <em>Candida</em> spp based upon in vivo studies showing a fungicidal effect proportional to the maximum (peak) plasma drug concentration and a persistent antifungal effect after plasma drug concentration falls below minimum inhibitory concentration (MIC) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/54\" class=\"abstract_t\">54</a>]. Fungicidal efficacy against <em>Candida</em> spp also appears to correlate with the area under time-concentration curve to minimum inhibitory concentration ratio (AUC:MIC) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/50\" class=\"abstract_t\">50</a>]. The optimal pharmacodynamic parameters for killing or inhibiting <em>Aspergillus</em> spp, however, are not clearly defined [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/54,55\" class=\"abstract_t\">54,55</a>]. Furthermore, therapeutic drug monitoring with standardized plasma drug concentration ranges or targets for echinocandins has not been established, and revised dosing strategies evaluated in animal models have not identified promising dosing tools for further assessment in humans [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/50,54\" class=\"abstract_t\">50,54</a>].</p><p class=\"headingAnchor\" id=\"H1239298150\"><span class=\"h1\">DOSING</span></p><p class=\"headingAnchor\" id=\"H18092677\"><span class=\"h2\">Adult dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dosing of echinocandins depends upon the indication. A brief overview of standard dosing approaches for echinocandins, including maintenance and loading doses and needed dose adjustments, is provided here. Clinicians should consult individual topic reviews for each infection for more detailed information about the use of each drug. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">&quot;Treatment and prevention of invasive aspergillosis&quot;</a>.)</p><p>Esophageal candidiasis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg intravenous (IV) loading dose, then 50 mg daily [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/4\" class=\"abstract_t\">4</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> &ndash; 150 mg IV daily; no loading dose is required [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/56\" class=\"abstract_t\">56</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; 200 mg IV daily [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/4\" class=\"abstract_t\">4</a>]</p><p/><p>Invasive candidiasis (including candidemia):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg IV loading dose on day 1, followed by 50 mg IV daily thereafter [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/57\" class=\"abstract_t\">57</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> &ndash; 100 mg intravenous dose daily; no loading dose is required [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/58,59\" class=\"abstract_t\">58,59</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; 200 mg IV loading dose on day 1, followed by 100 mg IV daily thereafter [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/60\" class=\"abstract_t\">60</a>]</p><p/><p>Salvage therapy for invasive aspergillosis (only <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> has US Food and Drug Administration [FDA] approval for this indication):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg IV dose on day 1, followed by 50 mg IV daily thereafter; daily dose can be increased to 70 mg if response is inadequate [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/61\" class=\"abstract_t\">61</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> &ndash; 150 mg IV dose daily; no loading dose is required [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/62,63\" class=\"abstract_t\">62,63</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; 200 mg IV loading dose on day 1, followed by 100 mg IV daily [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/64\" class=\"abstract_t\">64</a>]</p><p/><p>Neutropenic fever (empiric therapy):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> &ndash; 70 mg IV loading dose on day 1, followed by 50 mg IV daily thereafter (see <a href=\"topic.htm?path=treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients\" class=\"medical medical_review\">&quot;Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)&quot;</a>)</p><p/><p><em>Candida</em> prophylaxis in hematopoietic cell transplant recipients:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> <strong>&ndash;</strong> 50 mg IV daily (see <a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">&quot;Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1239299702\"><span class=\"h2\">Pediatric dosing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pharmacokinetic studies demonstrate an increased rate of clearance for <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> and <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> among neonates, infants, and younger children compared with adolescents and adults [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/65-72\" class=\"abstract_t\">65-72</a>]. Accordingly, larger doses of micafungin and caspofungin on the basis of milligrams per kilogram are required for small children and infants compared with adults. No large trials have evaluated dosing in low birthweight neonates, a population at high risk for developing invasive candidiasis. Both caspofungin and micafungin have FDA approval for use in children; dosing instructions for caspofungin are based upon body surface area for children aged three months or older [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. Micafungin is dosed in children four months or older according to body weight and the indications for use [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/53\" class=\"abstract_t\">53</a>].</p><p>Clinicians should consult the pediatric drug information topics (Lexicomp) or the individual topic reviews for each infection for more detailed information about the use of each drug. (See <a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Treatment of Candida infection in neonates&quot;</a> and <a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-management#H327877656\" class=\"medical medical_review\">&quot;Candidemia and invasive candidiasis in children: Management&quot;, section on 'Antifungal agents'</a>.)</p><p class=\"headingAnchor\" id=\"H1239299694\"><span class=\"h2\">Dose adjustments</span></p><p class=\"headingAnchor\" id=\"H1401995\"><span class=\"h3\">Enzyme induction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An increased maintenance dose of <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> of 70 mg daily is suggested for adult patients if treated concomitantly with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. For pediatric patients receiving rifampin, a dose of 70 <span class=\"nowrap\">mg/m<sup>2</sup></span> (up to 70 mg) of caspofungin is suggested. A similar adjustment of caspofungin is recommended if the patient is concurrently receiving other drugs that are potent inducers of cytochrome P450 3A4 metabolism (eg, <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a>, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a>, or <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>). (See <a href=\"#H1239300816\" class=\"local\">'Drug interactions'</a> below.)</p><p class=\"headingAnchor\" id=\"H1239298206\"><span class=\"h3\">Renal insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins are not extensively cleared by the kidney and are not dialyzable; therefore, dose adjustment is <strong>not</strong> required in patients with renal insufficiency, including patients who are receiving hemodialysis or continuous renal replacement therapy (continuous venovenous hemofiltration or continuous venovenous hemodialysis) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73,74\" class=\"abstract_t\">48,53,73,74</a>].</p><p class=\"headingAnchor\" id=\"H1239299710\"><span class=\"h3\">Hepatic insufficiency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is recommended that the <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> maintenance dose be reduced to 35 mg once daily for moderate hepatic insufficiency (Child-Pugh score 7 to 9). The loading dose is not reduced. No dose adjustment of caspofungin is recommended for mild hepatic insufficiency (Child-Pugh score &le;6), and no recommendation is available for use in severe hepatic insufficiency (Child-Pugh score &gt;9) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. A pharmacokinetic study in intensive care unit (ICU) patients suggested that preemptive dose reduction of caspofungin in ICU patients with moderate liver disease (Child-Pugh score 7 to 9) results in suboptimal drug exposures, suggesting that a scoring system developed for chronic liver disease may not be appropriate for guiding echinocandin dosing in patients with acute-onset liver dysfunction [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/75,76\" class=\"abstract_t\">75,76</a>].</p><p><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> does not require dose reduction for mild or moderate hepatic insufficiency, and no recommendation is available for use in severe hepatic insufficiency [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/53\" class=\"abstract_t\">53</a>].</p><p><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> is inactivated by gradual spontaneous degradation and not metabolized hepatically. Therefore, dose adjustment for hepatic insufficiency is not needed<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/73\" class=\"abstract_t\">73</a>].</p><p class=\"headingAnchor\" id=\"H1647359\"><span class=\"h3\">Obesity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Body weight is an important variable influencing the volume of distribution and clearance of all three echinocandins [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/77-79\" class=\"abstract_t\">77-79</a>]. Higher total body clearance of <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> has been reported among surgical intensive care unit patients who weigh &gt;75 kg [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/78\" class=\"abstract_t\">78</a>]. Similarly, in a pharmacokinetic study in patients with body mass index (BMI) &lt;25, 25 to 40, and &gt;40 <span class=\"nowrap\">kg/m<sup>2</sup>,</span> <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> clearance increased in proportion to weight in subjects weighing between 65 to 150 kg [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/79\" class=\"abstract_t\">79</a>]. Given these findings, we suggest a daily dose increase of 25 to 50 percent in patients weighing more than 75 kg with severe infection [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/80\" class=\"abstract_t\">80</a>]. However, we do not recommend such a dose increase for all obese patients because treatment outcomes did not differ between nonobese and obese subjects administered the same dose of caspofungin in clinical trials [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/81\" class=\"abstract_t\">81</a>].</p><p class=\"headingAnchor\" id=\"H1239298213\"><span class=\"h1\">ADVERSE EFFECTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins are well tolerated, and all three members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals.</p><p class=\"headingAnchor\" id=\"H1239299718\"><span class=\"h2\">Hepatotoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Modest asymptomatic elevations of aminotransferases (in 7 to 14 percent) and alkaline phosphatase (in 4 to 12 percent) are the most frequently reported laboratory abnormalities in healthy volunteers and patients treated with echinocandins [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. Liver function test abnormalities are generally less common in patients treated with echinocandins compared with those receiving amphotericin B formulations or azoles. Although rare, clinically significant hepatitis, hepatomegaly, hyperbilirubinemia, and hepatic failure have been reported with the echinocandins, although causality has not been conclusively established. Regular monitoring of hepatic aminotransferases during echinocandin therapy is suggested.</p><p class=\"headingAnchor\" id=\"H1239299726\"><span class=\"h2\">Infusion and hypersensitivity reactions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infusion-related histamine-release symptoms, including rash, pruritus, hypotension, bronchospasm, and angioedema, have been reported rarely with each of the echinocandins [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3\" class=\"abstract_t\">3</a>]. Such reactions have been reported with <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> when the drug is infused at a rate that exceeds 1.1 <span class=\"nowrap\">mg/minute</span> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/73\" class=\"abstract_t\">73</a>]. In most patients, these effects are transient and are easily managed by slowing the infusion rate and supportive care.</p><p>Delayed (type IV) hypersensitivity reactions manifesting as a maculopapular rash are rare, although eosinophilia has been observed in 3 percent of patients receiving <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/82\" class=\"abstract_t\">82</a>]. Anaphylaxis has been reported rarely with each of the echinocandins. Postmarketing reports for caspofungin include rare cases consistent with a hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome, and skin exfoliation, although it is not clear that these reactions were caused by caspofungin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Fever appears to be more common with <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> than other echinocandins, with rates ranging from 4 to 26 percent in clinical trials compared with &lt;1 percent for <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> and <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H1239298227\"><span class=\"h2\">Injection site pain</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Injection site pain and phlebitis have been reported more frequently with <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> (4 to 25 percent) than <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> (1 to 14 percent) or <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> (&lt;1 percent), particularly when caspofungin is administered through a peripheral catheter. If these adverse effects occur, the infusion can be slowed down or the echinocandin can be administered in a more dilute solution.</p><p><strong>Gastrointestinal</strong> &mdash; Nausea, vomiting, diarrhea, and abdominal pain have been reported in approximately 1 to 3 percent of patients receiving echinocandin therapy but rarely result in drug discontinuation<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>].</p><p class=\"headingAnchor\" id=\"H1239298234\"><span class=\"h2\">Renal toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No significant drug-related nephrotoxicity was observed with any of the echinocandins in clinical trials or documented in postmarketing surveillance [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>]. Modest rates of hypokalemia have been observed with all three drugs (2 to 11 percent), which may represent renal wasting.</p><p class=\"headingAnchor\" id=\"H1239298248\"><span class=\"h2\">Hematologic effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Anemia, leukopenia, neutropenia, and thrombocytopenia have been reported and are limited to rare case reports (&lt;1 percent) [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>].</p><p class=\"headingAnchor\" id=\"H3324455553\"><span class=\"h2\">Cardiac toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins have been associated with low rates of cardiac adverse effects, especially relative to amphotericin B and triazoles. Some acute cardiovascular events in patients may be associated with histamine release during intravenous infusion. A review of preclinical and animal studies suggested that <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> and <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> may have a greater potential for direct mitochondrial injury in cardiac myocytes compared with <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/84\" class=\"abstract_t\">84</a>]. However, the clinical significance of these observations is unknown, and documented cases of heart failure with caspofungin, anidulafungin, or micafungin are extremely rare (one to four cases per year for each echinocandin).</p><p class=\"headingAnchor\" id=\"H1239298262\"><span class=\"h1\">PREGNANCY</span></p><p class=\"headingAnchor\" id=\"H1239298269\"><span class=\"h2\">Fetal development</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no adequate studies of the echinocandins in pregnant women [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>]. Embryo-fetal development studies in rats and mice performed with doses twofold higher than human exposures resulted in skeletal changes in rat fetuses and increased abortion and visceral abnormalities in rabbits. Echinocandins appear to cross the placental barrier in rats and could be detected in the plasma of the fetus.</p><p>All three echinocandins are classified as pregnancy category class C agents; they should therefore only be used if the potential benefit justifies the risk to the fetus.</p><p class=\"headingAnchor\" id=\"H1239298276\"><span class=\"h2\">Breast milk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is not known whether <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, or <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> are excreted in human breast milk. However, all three echinocandins could be detected in the milk of lactating rats [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>]. Therefore, these drugs should only be administered to nursing mothers if the potential benefit justifies the risk.</p><p class=\"headingAnchor\" id=\"H1239298283\"><span class=\"h2\">Mutagenesis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins do not show evidence of mutagenic or genotoxic potential when evaluated by the standard battery of in vitro and in vivo tests [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,53,73\" class=\"abstract_t\">48,53,73</a>]. Fertility in rats is not affected by intravenous administration of any of the echinocandins. Long-term studies in animals to evaluate the carcinogenic potential of these echinocandins have not been performed.</p><p class=\"headingAnchor\" id=\"H1239300816\"><span class=\"h1\">DRUG INTERACTIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins are not significant inhibitors or inducers of cytochrome P450 metabolism or p-glycoprotein drug efflux transporters. As a result, echinocandins generally have a lower risk for pharmacokinetic drug-drug interactions compared with other systemic antifungals. Of the comparatively few significant drug interactions involving echinocandins that have been identified to date, most involve the effect of <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> or <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a> upon immunosuppressive agents or the effect of other drugs upon caspofungin via enzyme induction.</p><p>Echinocandin drug interactions will be briefly reviewed here. In addition, specific interactions of echinocandins with other medications may be determined using the drug interaction tool (Lexi-Interact Online). This tool can be accessed from the UpToDate online search page or through the individual drug information topics, section on Drug interactions.</p><p class=\"headingAnchor\" id=\"H1239301213\"><span class=\"h2\">Caspofungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mechanism(s) by which <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> interacts with other drugs have not been firmly established. It has been suggested that organic anion transporting polypeptides, such as OATP-1B1, which mediate uptake of some drugs to hepatocytes, may play a role in drug interactions of caspofungin<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/51,85\" class=\"abstract_t\">51,85</a>].</p><p><a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">Cyclosporine</a> is a substrate of OATP-1B1 transporters and, when administered concurrently with <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, has been shown to increase caspofungin's total plasma concentration exposure (also known as area under curve [AUC]) by approximately 35 percent [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. On the other hand, caspofungin caused no significant alteration of cyclosporine time versus plasma concentration profile [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. The US Food and Drug Administration (FDA)-approved product information recommends caution when caspofungin and cyclosporine are given concurrently due to potentially increased risk of hepatotoxicity as evidenced by transient elevations in hepatic aminotransferases. Should the benefits of concurrent therapy outweigh the risks, monitoring of liver function tests is warranted<strong> </strong>[<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,55\" class=\"abstract_t\">48,55</a>].</p><p><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin</a> decreases <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> serum concentrations by approximately 20 percent, a clinically significant effect given the narrow therapeutic index for tacrolimus. Regular monitoring of tacrolimus blood levels is necessary to avoid effects of subtherapeutic levels, including acute graft rejection [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48,55\" class=\"abstract_t\">48,55</a>].</p><p>Coadministration with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, an inhibitor of OATP-1, has been shown to induce <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a> metabolism though an unknown mechanism [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/86\" class=\"abstract_t\">86</a>]. Therefore, an increased maintenance dose of 70 mg per day of caspofungin is recommended in patients who are receiving concomitant rifampin [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/87\" class=\"abstract_t\">87</a>]. A similar dose increase is recommended in patients receiving other enzyme inducers, such as <a href=\"topic.htm?path=efavirenz-drug-information\" class=\"drug drug_general\">efavirenz</a>, <a href=\"topic.htm?path=nevirapine-drug-information\" class=\"drug drug_general\">nevirapine</a>, <a href=\"topic.htm?path=phenytoin-drug-information\" class=\"drug drug_general\">phenytoin</a>, <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, and <a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">carbamazepine</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"#H1401995\" class=\"local\">'Enzyme induction'</a> above.)</p><p class=\"headingAnchor\" id=\"H1239300837\"><span class=\"h2\">Micafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin</a> modestly reduces the clearance of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a> (rapamycin), and <a href=\"topic.htm?path=nifedipine-drug-information\" class=\"drug drug_general\">nifedipine</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/53\" class=\"abstract_t\">53</a>]. Routine dose adjustments of these agents are not necessary, but cyclosporine and sirolimus serum concentrations should be monitored. Unlike <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, micafungin does not affect <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> serum concentrations [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/88\" class=\"abstract_t\">88</a>]. For patients receiving micafungin and nifedipine, blood pressure should be monitored and the dose of nifedipine can be reduced if necessary [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H1239301205\"><span class=\"h2\">Anidulafungin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among the echinocandins, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> is the least likely to be an object, or cause, of a pharmacokinetic drug interaction because it is not a substrate, inhibitor, or inducer of cytochrome P450 or P-glycoprotein. Anidulafungin does not alter the metabolism or clearance of <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>. A modest increase (22 percent) in the total drug plasma concentration exposure (AUC) of anidulafungin was observed when coadministered with cyclosporine [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/89\" class=\"abstract_t\">89</a>]. The modest degree of this effect does not require dose adjustment or other specific management.</p><p>Concurrent administration of <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a>, or a variety of other substrates, inducers, or inhibitors of cytochrome P450 does not have a significant impact on the plasma drug concentration profile of <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a> [<a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H1239300844\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The development of echinocandins, the first systemic antifungal agents that selectively target the fungal cell wall, represents a major milestone in antifungal chemotherapy. Three semi-synthetic echinocandin derivatives have been developed for clinical use: <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">micafungin</a>, and <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>. Experience with this antifungal class suggests this it is the best tolerated and safest class available. (See <a href=\"#H1239292403\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically ill and neutropenic patients, and less commonly in salvage regimens for invasive aspergillosis. They are also used for empiric antifungal therapy in patients with febrile neutropenia. (See <a href=\"#H1239292410\" class=\"local\">'Overview of clinical uses'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The major advantages of echinocandins relative to other antifungal agents are their fungicidal activity against <em>Candida </em>spp, including fluconazole-resistant <em>C. glabrata</em> and <em>C. krusei</em>, combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions. (See <a href=\"#H1239292410\" class=\"local\">'Overview of clinical uses'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Because all three echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis (<a href=\"image.htm?imageKey=ID%2F107624\" class=\"graphic graphic_table graphicRef107624 \">table 1</a>). However, the three echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, it is important to appreciate these unique characteristics when selecting an echinocandin (<a href=\"image.htm?imageKey=ID%2F56212\" class=\"graphic graphic_table graphicRef56212 \">table 2</a>). (See <a href=\"#H1239292410\" class=\"local\">'Overview of clinical uses'</a> above and <a href=\"#H1239292494\" class=\"local\">'Pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Echinocandins are believed to elicit their antifungal activity by binding to the Fks p subunit of the enzyme, thereby blocking the b-(1,3)-D-glucan synthesis (<a href=\"image.htm?imageKey=ID%2F67408\" class=\"graphic graphic_figure graphicRef67408 \">figure 2</a>). These agents are fungicidal for susceptible <em>Candida</em> spp and fungistatic for <em>Aspergillus</em> spp. (See <a href=\"#H1239299741\" class=\"local\">'Mechanism of action'</a> above and <a href=\"#H1239292431\" class=\"local\">'Microbiologic activity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Echinocandins are well tolerated, and all three members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals. (See <a href=\"#H1239298213\" class=\"local\">'Adverse effects'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/1\" class=\"nounderline abstract_t\">Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/2\" class=\"nounderline abstract_t\">Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48:471.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/3\" class=\"nounderline abstract_t\">Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/4\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/5\" class=\"nounderline abstract_t\">Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001; 39 Suppl 1:55.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/6\" class=\"nounderline abstract_t\">Cabib E, Roh DH, Schmidt M, et al. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J Biol Chem 2001; 276:19679.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/7\" class=\"nounderline abstract_t\">Fleet GH. Composition and structure of yeast cell walls. Curr Top Med Mycol 1985; 1:24.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/8\" class=\"nounderline abstract_t\">Bernard M, Latg&eacute; JP. Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 2001; 39 Suppl 1:9.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/9\" class=\"nounderline abstract_t\">Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001; 183:2273.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/10\" class=\"nounderline abstract_t\">Beauvais A, Latg&eacute; JP. Membrane and cell wall targets in Aspergillus fumigatus. Drug Resist Updat 2001; 4:38.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/11\" class=\"nounderline abstract_t\">Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/12\" class=\"nounderline abstract_t\">Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2:e35.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/13\" class=\"nounderline abstract_t\">Wheeler RT, Kombe D, Agarwala SD, Fink GR. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog 2008; 4:e1000227.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/14\" class=\"nounderline abstract_t\">Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis 2008; 198:176.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/15\" class=\"nounderline abstract_t\">Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/16\" class=\"nounderline abstract_t\">Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/17\" class=\"nounderline abstract_t\">Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/18\" class=\"nounderline abstract_t\">Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/19\" class=\"nounderline abstract_t\">Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/20\" class=\"nounderline abstract_t\">Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/21\" class=\"nounderline abstract_t\">Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54:1360.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/22\" class=\"nounderline abstract_t\">Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/23\" class=\"nounderline abstract_t\">Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/24\" class=\"nounderline abstract_t\">Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/25\" class=\"nounderline abstract_t\">Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/26\" class=\"nounderline abstract_t\">Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/27\" class=\"nounderline abstract_t\">Pham CD, Iqbal N, Bolden CB, et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58:4690.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/28\" class=\"nounderline abstract_t\">Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/29\" class=\"nounderline abstract_t\">Beyda ND, John J, Kilic A, et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59:819.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/30\" class=\"nounderline abstract_t\">Wang E, Farmakiotis D, Yang D, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 2015; 70:2362.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/31\" class=\"nounderline abstract_t\">Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46:3634.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/32\" class=\"nounderline abstract_t\">Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/33\" class=\"nounderline abstract_t\">Nett J, Lincoln L, Marchillo K, Andes D. Beta -1,3 glucan as a test for central venous catheter biofilm infection. J Infect Dis 2007; 195:1705.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/34\" class=\"nounderline abstract_t\">Cassone A, Kerridge D, Gale EF. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol 1979; 110:339.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/35\" class=\"nounderline abstract_t\">Gale EF, Ingram J, Kerridge D, et al. Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes. J Gen Microbiol 1980; 117:383.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/36\" class=\"nounderline abstract_t\">Nett J, Lincoln L, Marchillo K, et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 2007; 51:510.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/37\" class=\"nounderline abstract_t\">Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/38\" class=\"nounderline abstract_t\">Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/39\" class=\"nounderline abstract_t\">Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/40\" class=\"nounderline abstract_t\">Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/41\" class=\"nounderline abstract_t\">Kahn JN, Hsu MJ, Racine F, et al. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50:2214.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/42\" class=\"nounderline abstract_t\">Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/43\" class=\"nounderline abstract_t\">Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44:2259.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/44\" class=\"nounderline abstract_t\">Schmatz DM, Powles M, McFadden DC, et al. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool 1991; 38:151S.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/45\" class=\"nounderline abstract_t\">Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem 2000; 275:40628.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/46\" class=\"nounderline abstract_t\">Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44:1850.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/47\" class=\"nounderline abstract_t\">Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of Systemic Antifungal Agents. Clin Infect Dis 2006; 43 Suppl 1:S28.</a></li><li class=\"breakAll\">Cancidas. Prescribing information-(caspofungin acetate) for injection. Merck &amp; Co Inc, Whitehouse Station, NJ 2008.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/49\" class=\"nounderline abstract_t\">Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/50\" class=\"nounderline abstract_t\">Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43:1647.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/51\" class=\"nounderline abstract_t\">Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/52\" class=\"nounderline abstract_t\">Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997.</a></li><li class=\"breakAll\">Mycamine (micafungin sodium) - Highlights of prescribing information. http://www.us.astellas.com/docs/mycamine.pdf (Accessed on April 21, 2015).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/54\" class=\"nounderline abstract_t\">Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23:805.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/55\" class=\"nounderline abstract_t\">Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27:369.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/56\" class=\"nounderline abstract_t\">de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005; 21:899.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/57\" class=\"nounderline abstract_t\">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/58\" class=\"nounderline abstract_t\">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/59\" class=\"nounderline abstract_t\">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/60\" class=\"nounderline abstract_t\">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/61\" class=\"nounderline abstract_t\">Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107:2888.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/62\" class=\"nounderline abstract_t\">Kontoyiannis DP, Ratanatharathorn V, Young JA, et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl Infect Dis 2009; 11:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/63\" class=\"nounderline abstract_t\">Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36:372.</a></li><li class=\"breakAll\">Anidulafungin plus voriconazole versus voriconazole for the treatment of invasive aspergillosis. In: Health NIo, ed, 2008. http://www.clinicaltrials.gov/ct2/show/NCT00531479 (Accessed on July 29, 2009).</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/65\" class=\"nounderline abstract_t\">Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010; 55:229.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/66\" class=\"nounderline abstract_t\">Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/67\" class=\"nounderline abstract_t\">Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53:1450.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/68\" class=\"nounderline abstract_t\">S&aacute;ez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/69\" class=\"nounderline abstract_t\">Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/70\" class=\"nounderline abstract_t\">Heresi GP, Gerstmann DR, Blumer JL, et al. Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants. Pediat Res 2003; 53:317A.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/71\" class=\"nounderline abstract_t\">Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/72\" class=\"nounderline abstract_t\">Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633.</a></li><li class=\"breakAll\">Eraxis. Prescribing information-(Anidulafungin) for injection. In: Pfizer I, ed. New York, NY 2008.</li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/74\" class=\"nounderline abstract_t\">Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 2013; 57:4053.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/75\" class=\"nounderline abstract_t\">Movshev BE, Dubrovina NA, Petrova VI, et al. [Plasma macroproteins in the evaluation of the effectiveness of therapeutic plasmapheresis in patients with rheumatoid arthritis]. Revmatologiia (Mosk) 1989; :32.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/76\" class=\"nounderline abstract_t\">Martial LC, Br&uuml;ggemann RJ, Schouten JA, et al. Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. Clin Pharmacokinet 2016; 55:723.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/77\" class=\"nounderline abstract_t\">Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44:590.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/78\" class=\"nounderline abstract_t\">Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60:100.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/79\" class=\"nounderline abstract_t\">Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2011; 55:5107.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/80\" class=\"nounderline abstract_t\">Amsden J, Slain D. Antifungal dosing in obesity: A review of the literature. Curr Infect Fungal Report 2011; 5:83.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/81\" class=\"nounderline abstract_t\">Ryan DM, Lupinacci RJ, Kartsonis NA. Efficacy and safety of caspofungin in obese patients. Med Mycol 2011; 49:748.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/82\" class=\"nounderline abstract_t\">Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/83\" class=\"nounderline abstract_t\">Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3:71.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/84\" class=\"nounderline abstract_t\">Cleary JD, Stover KR. Antifungal-Associated Drug-Induced Cardiac Disease. Clin Infect Dis 2015; 61 Suppl 6:S662.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/85\" class=\"nounderline abstract_t\">Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33:676.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/86\" class=\"nounderline abstract_t\">Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006; 19:763.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/87\" class=\"nounderline abstract_t\">Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48:4306.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/88\" class=\"nounderline abstract_t\">Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45:1018.</a></li><li><a href=\"https://www.uptodate.com/contents/pharmacology-of-echinocandins/abstract/89\" class=\"nounderline abstract_t\">Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13945 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1239300844\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1239292403\" id=\"outline-link-H1239292403\">INTRODUCTION</a></li><li><a href=\"#H1239292410\" id=\"outline-link-H1239292410\">OVERVIEW OF CLINICAL USES</a></li><li><a href=\"#H1239299741\" id=\"outline-link-H1239299741\">MECHANISM OF ACTION</a></li><li><a href=\"#H1239292431\" id=\"outline-link-H1239292431\">MICROBIOLOGIC ACTIVITY</a><ul><li><a href=\"#H1239292438\" id=\"outline-link-H1239292438\">Candida species</a><ul><li><a href=\"#H1239292445\" id=\"outline-link-H1239292445\">- Candida biofilms</a></li></ul></li><li><a href=\"#H1239292452\" id=\"outline-link-H1239292452\">Other yeasts</a></li><li><a href=\"#H1239292466\" id=\"outline-link-H1239292466\">Dimorphic fungi</a></li><li><a href=\"#H1239292473\" id=\"outline-link-H1239292473\">Aspergillus</a></li><li><a href=\"#H1239292480\" id=\"outline-link-H1239292480\">Other molds</a></li><li><a href=\"#H12264177\" id=\"outline-link-H12264177\">Pneumocystis jirovecii</a></li></ul></li><li><a href=\"#H1239292487\" id=\"outline-link-H1239292487\">RESISTANCE</a></li><li><a href=\"#H1239292494\" id=\"outline-link-H1239292494\">PHARMACOKINETICS</a><ul><li><a href=\"#H22267050\" id=\"outline-link-H22267050\">Caspofungin</a></li><li><a href=\"#H22267058\" id=\"outline-link-H22267058\">Micafungin</a></li><li><a href=\"#H22267066\" id=\"outline-link-H22267066\">Anidulafungin</a></li></ul></li><li><a href=\"#H1239298142\" id=\"outline-link-H1239298142\">PHARMACODYNAMICS</a></li><li><a href=\"#H1239298150\" id=\"outline-link-H1239298150\">DOSING</a><ul><li><a href=\"#H18092677\" id=\"outline-link-H18092677\">Adult dosing</a></li><li><a href=\"#H1239299702\" id=\"outline-link-H1239299702\">Pediatric dosing</a></li><li><a href=\"#H1239299694\" id=\"outline-link-H1239299694\">Dose adjustments</a><ul><li><a href=\"#H1401995\" id=\"outline-link-H1401995\">- Enzyme induction</a></li><li><a href=\"#H1239298206\" id=\"outline-link-H1239298206\">- Renal insufficiency</a></li><li><a href=\"#H1239299710\" id=\"outline-link-H1239299710\">- Hepatic insufficiency</a></li><li><a href=\"#H1647359\" id=\"outline-link-H1647359\">- Obesity</a></li></ul></li></ul></li><li><a href=\"#H1239298213\" id=\"outline-link-H1239298213\">ADVERSE EFFECTS</a><ul><li><a href=\"#H1239299718\" id=\"outline-link-H1239299718\">Hepatotoxicity</a></li><li><a href=\"#H1239299726\" id=\"outline-link-H1239299726\">Infusion and hypersensitivity reactions</a></li><li><a href=\"#H1239298227\" id=\"outline-link-H1239298227\">Injection site pain</a></li><li><a href=\"#H1239298234\" id=\"outline-link-H1239298234\">Renal toxicity</a></li><li><a href=\"#H1239298248\" id=\"outline-link-H1239298248\">Hematologic effects</a></li><li><a href=\"#H3324455553\" id=\"outline-link-H3324455553\">Cardiac toxicity</a></li></ul></li><li><a href=\"#H1239298262\" id=\"outline-link-H1239298262\">PREGNANCY</a><ul><li><a href=\"#H1239298269\" id=\"outline-link-H1239298269\">Fetal development</a></li><li><a href=\"#H1239298276\" id=\"outline-link-H1239298276\">Breast milk</a></li><li><a href=\"#H1239298283\" id=\"outline-link-H1239298283\">Mutagenesis</a></li></ul></li><li><a href=\"#H1239300816\" id=\"outline-link-H1239300816\">DRUG INTERACTIONS</a><ul><li><a href=\"#H1239301213\" id=\"outline-link-H1239301213\">Caspofungin</a></li><li><a href=\"#H1239300837\" id=\"outline-link-H1239300837\">Micafungin</a></li><li><a href=\"#H1239301205\" id=\"outline-link-H1239301205\">Anidulafungin</a></li></ul></li><li><a href=\"#H1239300844\" id=\"outline-link-H1239300844\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/13945|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/70049\" class=\"graphic graphic_figure\">- Echinocandins structure</a></li><li><a href=\"image.htm?imageKey=ID/67408\" class=\"graphic graphic_figure\">- Echinocandins target of activity</a></li></ul></li><li><div id=\"ID/13945|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/107624\" class=\"graphic graphic_table\">- Candida and Aspergillus echinocandin susceptibility</a></li><li><a href=\"image.htm?imageKey=ID/56212\" class=\"graphic graphic_table\">- Echinocandins PK</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antifungal-susceptibility-testing\" class=\"medical medical_review\">Antifungal susceptibility testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-management\" class=\"medical medical_review\">Candidemia and invasive candidiasis in children: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">Pharmacology of amphotericin B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-flucytosine-5-fc\" class=\"medical medical_review\">Pharmacology of flucytosine (5-FC)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients\" class=\"medical medical_review\">Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">Treatment and prevention of Pneumocystis pneumonia in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-invasive-aspergillosis\" class=\"medical medical_review\">Treatment and prevention of invasive aspergillosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">Treatment of Candida infection in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Treatment of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-neutropenic-fever-syndromes-in-adults-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients-high-risk-patients\" class=\"medical medical_review\">Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)</a></li></ul></div></div>","javascript":null}